Projektdarstellungen auf der Webseite

Jedes von der Gebert Rüf Stiftung geförderte Projekt wird mit einer Webdarstellung zugänglich gemacht, die über die Kerndaten des Projektes informiert. Mit dieser öffentlichen Darstellung publiziert die Stiftung die erzielten Förderresultate und leistet einen Beitrag zur Kommunikation von Wissenschaft in die Gesellschaft.


EVIIVE – Next-Generation Diagnostics for Early Disease Detection & Personalized Treatment Guidance


The project management is responsible for the content of the information provided.


  • Projekt-Nr: GRS-069/23 
  • Förderbeitrag: CHF 150'000 
  • Bewilligung: 31.10.2023 
  • Dauer: 09.2024 - 02.2026 
  • Handlungsfeld:  InnoBooster, seit 2018



Almost 80% of immunotherapy-eligible cancer patients are not responding to approved immunotherapy due to the lack of sensitive and specific biomarkers. At EVIIVE, we are developing a biomarker discovery platform focused on intercepting the ‘WhatsApp’ communication between immune cells and cancer cells in liquid biopsy, enabling the discovery of robust predictive biomarkers to build the next-generation personalized companion diagnostics for precision medicine. Our vision is to make every cancer patient effectively benefit the most from cutting-edge precision medicine.


Our pilot studies were collaborations with academic/clinical partners so far, for the next steps, we are aiming to complete our first collaborative study with one of the leading pharma to generate a pharma standard data package for us to gain industry-standard traction and to enter the regulatory approval process for our first companion diagnostic product (i.e. immunotherapy response prediction). EVIIVE is incorporating in 2024 Q3, with an alpha user (i.e. U.S.-based therapeutics) secured, collaboration with leading pharma and diagnostics providers in contract negotiation. EVIIVE will continue as a companion diagnostics provider for pharma and ultimately for patients in the clinics. Multiple VCs have shown interest in financing our seed funding round to accelerate the business development.


Am Projekt beteiligte Personen

Kevin Yim, Co-founder & CEO, University of Zurich
Richard Chahwan, Co-founder & CSO, University of Zurich

Letzte Aktualisierung dieser Projektdarstellung  17.06.2024